Skip to main content
Signal8

Lyra Therapeutics, Inc. (LYRA)

Sector: Biotechnology

Industry: Biotechnology

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

OTC:LYRAHealthcare
-84.21%$0.0300
CLOSED
Mkt Cap$337K
EV-
Float1.34M
O/S11.24M
VOL8K sh
$ Vol$244
RVOL1.97×
Inst Own-
SI0.4%
Net Cash/Sh-
EarningsNov 17 · Today
Dilution
Lyra Therapeutics, Inc. logoOTC:LYRAClosed$0.0300-84.21%
Historical Data
DateOpenHighLowCloseVolume
Nov 16, 20260.03000.03000.03000.03008,139
Nov 5, 20260.03000.19000.03000.1900401
Nov 2, 20260.03000.19000.03000.1900403
Oct 27, 20260.03000.19000.03000.190010,110
Oct 19, 20260.03000.19000.03000.19004,321
Oct 13, 20260.05100.19000.05100.1900420
Oct 9, 20260.03000.19000.03000.19002,100
Oct 8, 20260.03000.19500.03000.19502,102
Oct 5, 20260.14470.19000.14230.1900317
Oct 2, 20260.15000.15000.15000.1500348
Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
Not available
Ratings Distribution
BUY
2
HOLD
3
SELL
0
TOTAL5
Insider Trades
InsiderTypeShares
Smith W Bradford profile photoSmith W BradfordWithholding/Transfer640
Cavalier Jason profile photoCavalier JasonWithholding/Transfer667
Palasis Maria profile photoPalasis MariaWithholding/Transfer2.0K
Cavalier Jason profile photoCavalier JasonSale769
Palasis Maria profile photoPalasis MariaSale1.7K
PERCEPTIVE ADVISORS LLC profile photoPERCEPTIVE ADVISORS LLCSale28.6K
Shareholders
--
Institutional
(1)
--
Insiderⓘ
(2)
--
5%+ Owners
(3)
--
Unattributed (incl. retail)ⓘ
Top Shareholders
NameShares%
Palasis Maria profile photo
Palasis Maria
Principal Executive Officer, Director
1.1M--
Cavalier Jason profile photo
Cavalier Jason
Principal Financial Officer
517.9K--
SABBY MANAGEMENT, LLC logo
SABBY MANAGEMENT, LLC
· filed Jan 2026
175.2K9.9%
Samsara BioCapital, L.P. logo
Samsara BioCapital, L.P.
· may incl. warrants· stale · filed Nov 2024
65.6K5.0%
Pura Vida Investments, LLC logo
Pura Vida Investments, LLC
· filed Feb 2024
32.3K3.1%
Venrock Healthcare Capital Partners II, L.P. logo
Venrock Healthcare Capital Partners II, L.P.
· may incl. warrants· stale · filed Nov 2024
24.1K1.8%
Nantahala Capital Management, LLC logo
Nantahala Capital Management, LLC
· may incl. warrants· stale · filed Nov 2024
14.0K1.1%
COMERICA BANK logo
COMERICA BANK
23--
Sources: 13F, Form 4, 13D/13G
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis.

Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms.

It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.

The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Key Metrics
Market Cap$337,228
Enterprise Value--
P/E Ratio-0.02
Est. Net Cash/Share--
Institutional Ownership--

based on 11.24M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateMay 1, 2020
Shares Outstanding11.24M
Authorized Shares
Float1.34M
52-Week Range
$0.0004$4.59
$0.0300(1st percentile)
Volume
Average Daily Volume4.12K
8.14K today vs 4.12K avg(+97%)

30d Avg

4.12K

60d Avg

2.15K

90d Avg

1.53K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Lyra Therapeutics, Inc. (OTC: LYRA) traded at $0.0300 on Nov 16, 2026, down 84.21% from the previous close of $0.1900. 52-week range: $0.0004 to $4.59. The company is in the Healthcare sector (Biotechnology).